Literature DB >> 21365202

Tardive dyskinesia.

Pratibha G Aia1, Gonzalo J Revuelta, Leslie J Cloud, Stewart A Factor.   

Abstract

OPINION STATEMENT: Tardive dyskinesia (TD) is iatrogenic (drug-induced); hence the best strategy is prevention. Try to limit exposure to any dopamine receptor blocking agents (DRBAs) if possible. These agents may be unavoidable in some psychiatric conditions such as schizophrenia, but alternative therapies can be used in many situations, such as in the treatment of depression, anxiety, gastrointestinal conditions, and other neurologic conditions, including migraines and sleep disorders. When DRBAs are necessary, physicians should prescribe the smallest possible dose and try to taper and stop the drug at the earliest signs of TD. Abrupt cessation should be avoided, as this can worsen symptoms of TD. Always discuss and document the possibility of TD as an adverse effect when starting patients on DRBAs. If TD is mild and tolerable, the withdrawal of the offending agent is possible, and exposure to DRBAs was short, physicians should consider avoiding treatment and waiting for spontaneous recovery. When treatment is necessary, tetrabenazine (TBZ) is considered a potential first-line agent and is known to be one of the most effective drugs in treating TD, but it is expensive and adverse effects such as depression, akathisia and parkinsonism frequently occur. Therefore, second-line agents with better tolerability profiles are often tried first in practice. These include amantadine, benzodiazepines, beta-blockers, and levetiracetam. When using TBZ, adverse effects should be aggressively monitored. (Depression often can be managed with antidepressants, for instance). In patients with psychosis, withdrawal of the antipsychotic may not be possible. Switching to clozapine or quetiapine is one option to minimize TD. When these agents are contraindicated and the patient must continue using other atypical antipsychotic drugs, try to add dopamine-depleting agents such as TBZ or reserpine, but watch for the development of parkinsonism. When the symptoms are focal, such as tongue protrusion or blepharospasm, botulinum toxin injections can be very effective if spontaneous recovery does not occur. As a last resort, when disabling, life-threatening symptoms of TD persist despite all of the above-mentioned methods, some advocate resuming treatment with the DRBA to suppress symptoms of TD. This has the potential to worsen TD in the long run.

Entities:  

Year:  2011        PMID: 21365202     DOI: 10.1007/s11940-011-0117-x

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  38 in total

1.  Persistent muscular restlessness after phenothiazine treatment: report of 3 cases.

Authors:  W KRUSE
Journal:  Am J Psychiatry       Date:  1960-08       Impact factor: 18.112

2.  Propranolol, anxiety, and tardive dyskinesia.

Authors:  N A Bacher; H A Lewis
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

3.  Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.

Authors:  Sofia Pappa; Sofia Tsouli; George Apostolou; Venetsanos Mavreas; Spiridon Konitsiotis
Journal:  Clin Neuropharmacol       Date:  2010 Nov-Dec       Impact factor: 1.592

4.  Treatment of tardive dyskinesia with propranolol.

Authors:  F N Pitts
Journal:  J Clin Psychiatry       Date:  1982-08       Impact factor: 4.384

Review 5.  Vitamin E for neuroleptic-induced tardive dyskinesia.

Authors:  K V Soares; J J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2000

6.  Gender differences in tardive dyskinesia: a critical review of the literature.

Authors:  R Yassa; D V Jeste
Journal:  Schizophr Bull       Date:  1992       Impact factor: 9.306

7.  Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study.

Authors:  Christina W Slotema; Peter N van Harten; Richard Bruggeman; Hans W Hoek
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-10-13       Impact factor: 5.067

Review 8.  Tardive dyskinesia and new antipsychotics.

Authors:  Christoph U Correll; Eva M Schenk
Journal:  Curr Opin Psychiatry       Date:  2008-03       Impact factor: 4.741

9.  Clinical differences between metoclopramide- and antipsychotic-induced tardive dyskinesias.

Authors:  A E Lang
Journal:  Can J Neurol Sci       Date:  1990-05       Impact factor: 2.104

10.  Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.

Authors:  G K Thaker; J A Nguyen; M E Strauss; R Jacobson; B A Kaup; C A Tamminga
Journal:  Am J Psychiatry       Date:  1990-04       Impact factor: 18.112

View more
  16 in total

1.  Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2011-12-05       Impact factor: 4.030

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  High dose pyridoxine for the treatment of tardive dyskinesia: clinical case and review of literature.

Authors:  Musa U Umar; Aliyu A Isa; Asmaul H Abba
Journal:  Ther Adv Psychopharmacol       Date:  2015-12-14

4.  Repetitive transcranial magnetic stimulation for treatment of tardive syndromes: double randomized clinical trial.

Authors:  Eman M Khedr; Bastawy Al Fawal; Ahmed Abdelwarith; Mostafa Saber; John C Rothwell
Journal:  J Neural Transm (Vienna)       Date:  2018-10-13       Impact factor: 3.575

5.  Alteration of Cytokines Levels in the Striatum of Rats: Possible Participation in Vacuous Chewing Movements Induced by Antipsycotics.

Authors:  Luis Ricardo Peroza; Larissa Finger Schaffer; Catiuscia Molz De Freitas; Caroline Queiroz Leal; Mayara Calegaro Ferrari; Marta Maria Frescura Duarte; Roselei Fachinetto
Journal:  Neurochem Res       Date:  2016-05-26       Impact factor: 3.996

Review 6.  Valbenazine: First Global Approval.

Authors:  Esther S Kim
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

7.  Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia.

Authors:  Tanuja Bordia; Danhui Zhang; Xiomara A Perez; Maryka Quik
Journal:  Exp Neurol       Date:  2016-09-19       Impact factor: 5.330

Review 8.  Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

9.  An update on tardive dyskinesia: from phenomenology to treatment.

Authors:  Olga Waln; Joseph Jankovic
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-07-12

Review 10.  Treatment of neurolept-induced tardive dyskinesia.

Authors:  Stacey K Jankelowitz
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.